文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 呼吸道合胞病毒单克隆抗体使用说明书
侵权投诉

呼吸道合胞病毒单克隆抗体使用说明书

呼吸道合胞病毒单克隆抗体使用说明书

Injectable Medication Guideline:

Synagis (Palivizumab)

Background:

Respiratory syncytial virus (RSV) is a common disease of childhood and causes acute upper respiratory tract infections in patients of all ages. Most RSV-infected infants experience upper respiratory tract symptoms, and 20% to 30% develop lower respiratory tract infections with their first RSV infection. Certain conditions increase the risk of severe or fatal RSV infection. These include preterm birth; cyanotic or complicated congenital heart disease, especially when the condition causes pulmonary hypertension; chronic lung disease of prematurity, and immunodeficiency disease or therapy causing immunosuppression at any age. In the U.S., more than 125,000 hospitalizations due to RSV infection occur annually. Outbreaks of RSV usually begin in November or December, peak in January or February, and end in March or April.

Synagis (palivizumab), a humanized mouse RSV monoclonal antibody, has been shown to reduce the risk of serious RSV disease and to reduce RSV-related hospitalizations in high-risk infants and children. Synagis is administered at a dose of 15mg/kg once every 30 days. Five monthly doses will provide more than 20 weeks of protective serum antibody concentration for most infants. Synagis is administered intramuscularly (IM). Synagis is not effective in the treatment of RSV and it is not approved or recommended for this indication. Synagis is FDA-approved for the prevention of serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV disease. Safety and efficacy were established in infants with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (≤ 35 weeks gestation), and children with hemodynamically significant congenital heart disease (CHD). Synagis is associated with high cost. Patients receiving Synagis must meet strict approval criteria.

Criteria (based on documented RSV risk factors):

Infants born at 28 weeks gestation or earlier and who are less than 12 months of age as of November

1st. A maximum of five monthly doses is recommended for patients in this category.

Infants born between 29 to 32 weeks gestation and who are less than 6 months of age as of

November 1st. A maximum of five monthly doses is recommended for patients in this category.

Infants born between 32 to 35 weeks gestation and who are less than 3 months of age as of

November 1st and who have one of the following two risk factors for hospitalization due to RSV:

Infant attends child care, defined as a home or facility where care is provided for any number of

infants or young toddlers in the child care facility; or

Infant has school age siblings or school age relatives living in the house

Infants in this category may receive prophylaxis with Synagis until they reach 3 months of age

and should receive a maximum of 3 monthly doses.

Infants with chronic lung disease (CLD) who are less than 2 years of age as of November 1st who are

receiving or have received medical therapy for CLD within the past 6 months (includes supplemental oxygen, nebulizer treatments, bronchodilators, diuretics, or chronic corticosteroid therapy). A maximum of five monthly doses is recommended for patients in this category.

Infants born before 35 weeks gestation who have congenital abnormalities of the airway or

neuromuscular disease. A maximum of five monthly doses is recommended for patients in this category.

Infants and children who are less than 2 years of age as of November 1st with hemodynamically

significant cyanotic or acyanotic congenital heart disease. Those most likely to benefit are infants and children receiving medication for congestive heart failure (digoxin, diuretic), those with moderate to severe pulmonary hypertension, and those with cyanotic heart disease. A maximum of five monthly doses is recommended for patients in this category.

Infants and children with immune deficiency who may benefit from RSV prophylaxis (severe

combined immunodeficiency, acquired immunodeficiency syndrome (HIV/AIDS), transplant recipients, or children immunocompromised due to chemotherapy). A maximum of five monthly doses is recommended for patients in this category.

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email